Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
M W CarrollC E Barry

Abstract

To determine the frequency of and risk factors for major adverse drug reactions (MADRs) associated with anti-tuberculosis treatment at a tuberculosis (TB) referral hospital in the Republic of Korea. Data from an ongoing natural history cohort study were analyzed for permanent regimen changes due to adverse drug reactions and confirmed by chart review. Among 655 subjects, there were 132 MADRs in 112 (17%) subjects. The most common MADRs were gastrointestinal (n = 53), musculoskeletal (n = 22), psychiatric (n = 10), visual (n = 9) and peripheral neuropathic (n = 8). MADRs were more frequent in subjects being treated with second-line regimens (16%) compared to first-line regimens (2.5%). Drugs frequently associated with MADRs were amikacin (3/10, 30%), linezolid (8/29, 28%), para-aminosalicylic acid (47/192, 24%), pyrazinamide (31/528, 5.8%), macrolides (2/44, 4.5%) and cycloserine (12/272, 4.4%). Fluoroquinolones accounted for a single MADR (1/377, 0.003%), despite widespread usage. In multivariate analysis, infection with multi- or extensively drug-resistant disease and previous history of anti-tuberculosis treatment were risk factors for MADR, with adjusted hazard ratios of respectively 2.2 (P = 0.02) and 1.6 (P = 0.04). MA...Continue Reading

Citations

Sep 27, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ben GoldCarl F Nathan
May 23, 2014·Drugs·Abdullah Alsultan, Charles A Peloquin
Jan 6, 2016·International Journal of Environmental Research and Public Health·Tao ZhangXiujun Li
Mar 25, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Kocfa Chung-DelgadoAntonio Bernabe-Ortiz
Jun 10, 2014·Journal of Ethnopharmacology·Nneka N IbekweUNKNOWN collaboration with 73 Visited Herbalists
Jul 28, 2016·Expert Opinion on Drug Safety·H Simon SchaafAnthony J Garcia-Prats
Apr 19, 2017·Tuberculosis and Respiratory Diseases·Bo Hyoung KangTae Sun Shim
Jun 15, 2018·Current Opinion in Allergy and Clinical Immunology·Sowmya Nagarajan, Paul Whitaker
May 30, 2015·The European Respiratory Journal·Anne-Fleur van der PaardtJan-Willem C Alffenaar
Mar 13, 2019·Antimicrobial Agents and Chemotherapy·Wael A AlghamdiCharles A Peloquin
Dec 21, 2019·Revista Da Sociedade Brasileira De Medicina Tropical·Ronise Malaquias Carlos ValadaresSilvana Spíndola de Miranda
Jul 25, 2019·The American Journal of Tropical Medicine and Hygiene·María Luisa AznarIsrael Molina Romero
May 15, 2013·Palliative Medicine·Jackie RobinsonChristine Ingleton
Jan 27, 2019·Public Health Nursing·Mei FengJinHong Xu
May 19, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Yang ZhangSiyan Zhan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.